Proteotoxicity and cardiac dysfunction - Alzheimer's disease of the heart?

New England Journal of Medicine

Volumn 368, Issue 5, 2013, Pages 455-464

  Willis, Monte S ^a   Patterson, Cam ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA B CRYSTALLIN; ATROGIN 1; C TERMINAL OF HSP70 INTERACTING PROTEIN; CHAPERONE; DESMIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN A4; HEAT SHOCK PROTEIN B1; HEAT SHOCK PROTEIN B2; IVACAFTOR; LUMACAFTOR; MUSCLE RING FINGER 1 PROTEIN; MUSCLE RING FINGER 2 PROTEIN; MUSCLE RING FINGER 3 PROTEIN; OLIGOMER; PROTEASOME; PROTEIN CRYAB; PROTEIN MDM2; SMALL HEAT SHOCK PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UNC 45 PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AUTOPHAGY; CARDIOMYOPATHY; CELL DEATH; CONGENITAL HEART DISEASE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; ENVIRONMENTAL ENRICHMENT; EXERCISE; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; HUNTINGTON CHOREA; HYPERTROPHIC CARDIOMYOPATHY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN METABOLISM; PROTEIN MISFOLDING; PROTEIN SYNTHESIS REGULATION; PROTEOTOXICITY; QUALITY CONTROL; REVIEW;

EID: 84873034262     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1106180     Document Type: Review

References (91)

1. Cole DR, Singian EB, Katz LN. The long-term prognosis following myocardial infarction, and some factors which affect it. Circulation 1954;9:321-34.
2. Weiss MM. Ten-year prognosis of acute myocardial infarction. Am J Med Sci 1956;231:9-12.
3. Dimond GE. Prognosis of men returning to work after first myocardial infarction. Circulation 1961;23:881-5.
4. Boudrez H, De Backer G. Recent findings on return to work after an acute myocardial infarction or coronary artery bypass grafting. Acta Cardiol 2000;55:341-9.
5. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011;123(4):e18-e209. [Errata, Circulation 2011;123(6):e240, 124(16):e426.]
6. David R, Franz WM. From pluripotency to distinct cardiomyocyte subtypes. Physiology (Bethesda) 2012;27:119-29.
7. Samarel AM, Parmacek MS, Magid NM, Decker RS, Lesch M. Protein synthesis and degradation during starvation-induced cardiac atrophy in rabbits. Circ Res 1987;60:933-41.
8. Preedy VR, Smith DM, Kearney NF, Sugden PH. Rates of protein turnover in vivo and in vitro in ventricular muscle of hearts from fed and starved rats. Biochem J 1984;222:395-400.
9. Karim MA, Ferguson AG, Wakim BT, Samarel AM. In vivo collagen turnover during development of thyroxine-induced left ventricular hypertrophy. Am J Physiol 1991;260:C316-C326.
10. Magid NM, Wallerson DC, Borer JS. Myofibrillar protein turnover in cardiac hypertrophy due to aortic regurgitation. Cardiology 1993;82:20-9.
11. Wiseman RL, Powers ET, Buxbaum JN, Kelly JW, Balch WE. An adaptable standard for protein export from the endoplasmic reticulum. Cell 2007;131:809-21.
12. Kampinga HH, Hageman J, Vos MJ, et al. Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones 2009;14:105-11.
13. Taylor RP, Benjamin IJ. Small heat shock proteins: a new classification scheme in mammals. J Mol Cell Cardiol 2005;38:433-44.
14. Vos MJ, Kanon B, Kampinga HH. HSPB7 is a SC35 speckle resident small heat shock protein. Biochim Biophys Acta 2009;1793:1343-53. [Erratum, Biochim Biophys Acta 2009;1793:1929-30.]
15. Kumarapeli AR, Wang X. Genetic modification of the heart: chaperones and the cytoskeleton. J Mol Cell Cardiol 2004;37:1097-109.
16. Golenhofen N, Arbeiter A, Koob R, Drenckhahn D. Ischemia-induced association of the stress protein alpha B-crystallin with I-band portion of cardiac titin. J Mol Cell Cardiol 2002;34:309-19.
17. Wang X, Klevitsky R, Huang W, Glasford J, Li F, Robbins J. AlphaB-crystallin modulates protein aggregation of abnormal desmin. Circ Res 2003;93:998-1005.
18. Vicart P, Caron A, Guicheney P, et al. A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. Nat Genet 1998;20:92-5.
19. Barral JM, Hutagalung AH, Brinker A, Hartl FU, Epstein HF. Role of the myosin assembly protein UNC-45 as a molecular chaperone for myosin. Science 2002;295:669-71.
20. Willis MS, Schisler JC, Portbury AL, Patterson C. Build it up - tear it down: protein quality control in the cardiac sarcomere. Cardiovasc Res 2009;81:439-48.
21. Ciechanover A, Heller H, Katz-Etzion R, Hershko A. Activation of the heat-stable polypeptide of the ATP-dependent proteolytic system. Proc Natl Acad Sci U S A 1981;78:761-5.
22. Hershko A, Ciechanover A, Rose IA. Identification of the active amino acid residue of the polypeptide of ATP-dependent protein breakdown. J Biol Chem 1981;256:1525-8.
23. Idem. Resolution of the ATP-dependent proteolytic system from reticulocytes: a component that interacts with ATP. Proc Natl Acad Sci U S A 1979;76:3107-10.
24. Rodríguez JE, Schisler JC, Patterson C, Willis MS. Seek and destroy: the ubiquitin-proteasome system in cardiac disease. Curr Hypertens Rep 2009;11:396-405.
25. Fielitz J, Kim MS, Shelton JM, et al. Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. J Clin Invest 2007;117:2486-95.
26. Kedar V, McDonough H, Arya R, Li HH, Rockman HA, Patterson C. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc Natl Acad Sci U S A 2004;101:18135-40.
27. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42.
28. Mizushima N, Klionsky DJ. Protein turnover via autophagy: implications for metabolism. Annu Rev Nutr 2007;27:19-40.
29. Iwata A, Riley BE, Johnston JA, Kopito RR. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 2005;280:40282-92.
30. Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004;36:585-95.
31. Shimomura H, Terasaki F, Hayashi T, Kitaura Y, Isomura T, Suma H. Autophagic degeneration as a possible mechanism of myocardial cell death in dilated cardiomyopathy. Jpn Circ J 2001;65:965-8.
32. Saijo M, Takemura G, Koda M, et al. Cardiomyopathy with prominent autophagic degeneration, accompanied by an elevated plasma brain natriuretic peptide level despite the lack of overt heart failure. Intern Med 2004;43:700-3.
33. Kostin S, Pool L, Elsässer A, et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res 2003;92:715-24.
34. Kassiotis C, Ballal K, Wellnitz K, et al. Markers of autophagy are downregulated in failing human heart after mechanical unloading. Circulation 2009;120:Suppl:S191-S197.
35. Matsui Y, Takagi H, Qu X, et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res 2007;100:914-22.
36. Huang C, Liu W, Perry CN, et al. Autophagy and protein kinase C are required for cardioprotection by sulfaphenazole. Am J Physiol Heart Circ Physiol 2010;298:H570-H579.
37. Decker RS, Wildenthal K. Lysosomal alterations in hypoxic and reoxygenated hearts. I. Ultrastructural and cytochemical changes. Am J Pathol 1980;98:425-44.
38. Huang C, Yitzhaki S, Perry CN, et al. Autophagy induced by ischemic preconditioning is essential for cardioprotection. J Cardiovasc Transl Res 2010;3:365-73.
39. Yan L, Vatner DE, Kim SJ, et al. Autophagy in chronically ischemic myocardium. Proc Natl Acad Sci U S A 2005;102:13807-12.
40. Lu L, Wu W, Yan J, Li X, Yu H, Yu X. Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. Int J Cardiol 2009;134:82-90.
41. Nowis D, Maczewski M, Mackiewicz U, et al. Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 2010;176:2658-68.
42. Kaganovich D, Kopito R, Frydman J. Misfolded proteins partition between two distinct quality control compartments. Nature 2008;454:1088-95.
43. Ding WX, Yin XM. Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome. Autophagy 2008;4:141-50.
44. Li J, Horak KM, Su H, Sanbe A, Robbins J, Wang X. Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice. J Clin Invest 2011;121:3689-700.
45. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003;26:267-98.
46. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-12.
47. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med 2004;10:Suppl:S10-S17.
48. Idem. Opinion: what is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol 2005;6:891-8.
49. Douglas PM, Summers DW, Cyr DM. Molecular chaperones antagonize proteotoxicity by differentially modulating protein aggregation pathways. Prion 2009;3:51-8.
50. Tsunemi T, Ashe TD, Morrison BE, et al. PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med 2012;4:142ra97.
51. Fatouros C, Pir GJ, Biernat J, et al. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity. Hum Mol Genet 2012;21:3587-603.
52. Bucciantini M, Giannoni E, Chiti F, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002;416:507-11.
53. Conway KA, Lee SJ, Rochet JC, et al. Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann N Y Acad Sci 2000;920:42-5.
54. Sanbe A, Osinska H, Saffitz JE, et al. Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A 2004;101:10132-6.
55. Tannous P, Zhu H, Nemchenko A, et al. Intracellular protein aggregation is a proximal trigger of cardiomyocyte autophagy. Circulation 2008;117:3070-8.
56. Wang X, Osinska H, Klevitsky R, et al. Expression of R120G-alphaB- crystallin causes aberrant desmin and alphaB-crystallin aggregation and cardiomyopathy in mice. Circ Res 2001;89:84-91.
57. Wang X, Osinska H, Dorn GW II, et al. Mouse model of desmin-related cardiomyopathy. Circulation 2001;103:2402-7.
58. Finsterer J, Stöllberger C. Primary myopathies and the heart. Scand Cardiovasc J 2008;42:9-24.
59. Zhang H, Rajasekaran NS, Orosz A, Xiao X, Rechsteiner M, Benjamin IJ. Selective degradation of aggregate-prone Cry-AB mutants by HSPB1 is mediated by ubiquitin proteasome pathways. J Mol Cell Cardiol 2010;49:918-30.
60. Chen Q, Liu JB, Horak KM, et al. Intrasarcoplasmic amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake. Circ Res 2005;97:1018-26.
61. den Engelsman J, Keijsers V, de Jong WW, Boelens WC. The small heat-shock protein alpha B-crystallin promotes FBX4-dependent ubiquitination. J Biol Chem 2003;278:4699-704.
62. Willis MS, Schisler JC, Li L, et al. Cardiac muscle ring finger-1 increases susceptibility to heart failure in vivo. Circ Res 2009;105:80-8.
63. Willis MS, Ike C, Li L, Wang DZ, Glass DJ, Patterson C. Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ Res 2007;100:456-9.
64. Pattison JS, Sanbe A, Maloyan A, Osinska H, Klevitsky R, Robbins J. Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation 2008;117:2743-51.
65. Bulteau AL, Lundberg KC, Humphries KM, et al. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem 2001;276:30057-63.
66. Tian Z, Zheng H, Li J, Li YF, Su H, Wang X. Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice. Circ Res 2012;111:532-42.
67. Fu L, Liang JJ. Alteration of protein-protein interactions of congenital cataract crystallin mutants. Invest Ophthalmol Vis Sci 2003;44:1155-9.
68. Idem. Detection of protein-protein interactions among lens crystallins in a mammalian two-hybrid system assay. J Biol Chem 2002;277:4255-60.
69. Sanbe A, Daicho T, Mizutani R, et al. Protective effect of geranylgeranylacetone via enhancement of HSPB8 induction in desmin-related cardiomyopathy. PLoS One 2009;4(4):e5351.
70. Ooie T, Takahashi N, Saikawa T, et al. Single oral dose of geranylgeranylacetone induces heat-shock protein 72 and renders protection against ischemia/reperfusion injury in rat heart. Circulation 2001;104:1837-43.
71. Mohamed BA, Barakat AZ, Zimmermann WH, et al. Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis. J Mol Cell Cardiol 2012;53:459-68.
72. Maesako M, Uemura K, Kubota M, et al. Exercise is more effective than diet control in preventing high fat diet-induced β-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice. J Biol Chem 2012;287:23024-33.
73. Buchman AS, Boyle PA, Yu L, Shah RC, Wilson RS, Bennett DA. Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology 2012;78:1323-9.
74. Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci 2005;25:4217-21.
75. Jankowsky JL, Melnikova T, Fadale DJ, et al. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci 2005;25:5217-24.
76. van Dellen A, Blakemore C, Deacon R, York D, Hannan AJ. Delaying the onset of Huntington's in mice. Nature 2000;404:721-2.
77. Pang TY, Stam NC, Nithianantharajah J, Howard ML, Hannan AJ. Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice. Neuroscience 2006;141:569-84.
78. Rockenstein E, Torrance M, Mante M, et al. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J Neurosci Res 2006;83:1252-61.
79. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486-9.
80. Sanbe A, Osinska H, Villa C, et al. Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. Proc Natl Acad Sci U S A 2005;102:13592-7.
81. Maloyan A, Gulick J, Glabe CG, Kayed R, Robbins J. Exercise reverses preamyloid oligomer and prolongs survival in alphaB-crystallin-based desmin-related cardiomyopathy. Proc Natl Acad Sci U S A 2007;104:5995-6000.
82. Buschert V, Bokde AL, Hampel H. Cognitive intervention in Alzheimer disease. Neurology 2010;6:508-17.
83. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992;358:761-4.
84. Denning GM, Ostedgaard LS, Welsh MJ. Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia. J Cell Biol 1992;118:551-9.
85. Lukacs GL, Chang XB, Bear C, et al. The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane: determination of functional half-lives on transfected cells. J Biol Chem 1993;268:21592-8.
86. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67:12-8.
87. Lubamba B, Dhooghe B, Noel S, Leal T. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem 2012;45:1132-44.
88. Ho L, Pasinetti GM. Polyphenolic compounds for treating neurodegenerative disorders involving protein misfolding. Expert Rev Proteomics 2010;7:579-89.
89. Lublin A, Isoda F, Patel H, et al. FDA-approved drugs that protect mammalian neurons from glucose toxicity slow aging dependent on CBP and protect against proteotoxicity. PLoS One 2011;6(11):e27762.
90. Crowe A, Ballatore C, Hyde E, Trojanowski JQ, Lee VM. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem Biophys Res Commun 2007;358:1-6.
91. Pickhardt M, Gazova Z, von Bergen M, et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J Biol Chem 2005;280:3628-35.